Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: ARCHIVE

Chris Marlett, MDB Capital
investorpress clippingsvideoARCHIVE
ARCHIVE: Slack Capital interview: Chris Marlett, Chairman of the BoardMay 22, 2025
ARCHIVE: Slack Capital interview: Damien Perriman, CCO
investorpress clippingsvideoARCHIVEperriman
ARCHIVE: Slack Capital interview: Damien Perriman, CCOMay 20, 2025
Michael Heltzen & Erum Azeez Khan
heltzenpress releaseinvestorpress clippingsvideoARCHIVEpodcast
ARCHIVE: Podcast: eXoZymes highlights scalable biomanufacturing platform and first spinout, NCTx, on 'Grow Everything'May 16, 2025
Tyler Korman
investorpress clippingsvideoARCHIVEkorman
ARCHIVE: Slack Capital interview: Tyler Korman, VP of ResearchMay 15, 2025
ARCHIVE: Transcript: eXoZymes 1st quarter 2025 and NCTx subsidiary update
investorARCHIVE
ARCHIVE: Transcript: eXoZymes 1st quarter 2025 and NCTx subsidiary updateMay 14, 2025
ARCHIVE: Slack Capital: EXOZ investment report and CEO interview
heltzeninvestorpress clippingsvideoARCHIVE
ARCHIVE: Slack Capital: EXOZ investment report and CEO interviewMay 13, 2025
ARCHIVE: eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST today
press releaseinvestorARCHIVE
ARCHIVE: eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST todayMay 12, 2025
ARCHIVE: eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM EST
press releaseinvestorARCHIVE
ARCHIVE: eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM ESTMay 7, 2025
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health
press releaseinvestornutraceuticalsmedicinescienceARCHIVE
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver healthMay 6, 2025
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscienceARCHIVE
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Previous page
Page 1 of 7
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark